Patents Assigned to Cornell University
  • Inhibitors of soluble adenylyl cyclase
    Patent number: 10981899
    Abstract: Provided are 6-amino substituted 2,6-diamino-4-chloropyrimidine compounds which are specific inhibitors of soluble adenylyl cyclase. The compounds can be formulated with pharmaceutical carriers and used for reducing cyclic AMP levels. The compositions can be used for treatment of various conditions including ocular hypotony.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: April 20, 2021
    Assignees: Cornell University, Tri-Institutional Therapeutics Discovery Institute
    Inventors: Jochen Buck, Lonny Levin, Lavoisier Ramos-Espiritu, Clemens Steegborn, Ayumu Sato, Rei Okamoto, Mayako Michino
  • Sensors with elastomeric foams and uses thereof
    Patent number: 10976207
    Abstract: Provided are sensors and articles of manufacture comprising one or more sensors. Also provided are uses of the sensors. The sensors have an elastomeric foam and one or more light sources and one or more light receivers. In various examples, the light source(s) and light receiver(s) are disposed on and/or disposed in and/or partially disposed in the elastomeric foam.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: April 13, 2021
    Assignee: Cornell University
    Inventors: Bryan Peele, Robert Shepherd, Ilse Van Meerbeek
  • NS1 truncated virus for the development of canine influenza vaccines
    Patent number: 10973903
    Abstract: The present invention relates to compositions and methods for the treatment and prevention of canine influenza virus (CIV) and CIV-related pathology. The present invention is based on the development of mutant CIV, having one or more mutations in segment 8, which induces a CIV-specific immune response in a subject.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: April 13, 2021
    Assignees: University of Rochester, Cornell University
    Inventors: Luis Martinez-Sobrido, Aitor Nogales-Gonzalez, Colin Parrish
  • Nucleic acids, vectors, host cells, and methods for recombinantly producing water-soluble membrane proteins
    Patent number: 10961286
    Abstract: The present invention relates to a nucleic acid construct having a chimeric nucleic acid molecule comprising a first nucleic acid moiety encoding an amphipathic shield domain protein; a second nucleic acid moiety encoding an integral membrane protein; and a third nucleic acid moiety encoding a water soluble expression decoy protein, as well as a chimeric nucleic acid molecule having a first nucleic acid moiety encoding an amphipathic shield domain protein and a second nucleic acid moiety encoding an integral membrane protein. The present invention further relates to an expression vector, a host cell, and a protein encoded by the nucleic acid construct. Also disclosed is a method of recombinantly producing an integral membrane protein in soluble form.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: March 30, 2021
    Assignee: Cornell University
    Inventors: Matthew Delisa, Dario Mizrachi
  • ?-nicotinate ester nucleotides and process for preparing same
    Patent number: 10961268
    Abstract: The invention provides a compound of formula (I): wherein R is as described herein. The invention also provides a process for the preparation of the compound.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: March 30, 2021
    Assignee: Cornell University
    Inventor: Anthony A. Sauve
  • IRE1 small molecule inhibitors
    Patent number: 10961218
    Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.
    Type: Grant
    Filed: July 16, 2020
    Date of Patent: March 30, 2021
    Assignee: Cornell University
    Inventors: Joseph P. Vacca, Dansu Li, Sarah Elizabeth Bettigole
  • Pulsed lasers based on spatiotemporal mode-locking
    Patent number: 10965092
    Abstract: The technology disclosed in this patent document allows mode locking of both selected longitudinal and transverse modes to produce laser pulses. The laser light produced based on such mode locking exhibits a 3-dimensional mode profile based on the locked longitudinal and transverse modes.
    Type: Grant
    Filed: December 31, 2018
    Date of Patent: March 30, 2021
    Assignee: Cornell University
    Inventors: Logan Wright, Frank Wise
  • Floating gate based sensor apparatus and related floating gate based sensor applications
    Patent number: 10962501
    Abstract: A floating gate based sensor apparatus includes at least two separate electrical bias components with respect to a floating gate based sensor surface within the floating gate based sensor apparatus. By including the at least two electrical bias components, the floating gate based sensor apparatus provides enhanced capabilities for biomaterial and non-biomaterial detection and manipulation while using the floating gate based sensor apparatus.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: March 30, 2021
    Assignee: Cornell University
    Inventors: Krishna Jayant, Edwin C. Kan
  • Method to enhance wound healing using silk-derived protein
    Patent number: 10953132
    Abstract: Described herein are methods of enhancing wound healing using silk-derived proteins (SDP), including low molecular weight SDP fragments. Also described are compositions for the treatment of wounds, including corneal wounds, skin wounds, surgical incisions, burns, and skin ulcers, comprising SDP fragments, including low molecular weight SDP fragments.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: March 23, 2021
    Assignees: Cornell University, Silk Technologies, Ltd.
    Inventors: Waleed Abdel-Naby, Mark Rosenblatt, Brian D. Lawrence, David W. Infanger
  • Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK)
    Patent number: 10954567
    Abstract: Described herein are mutations that confer resistance to treatment with a BTK inhibitor. Described herein are modified BTK polypeptides that exhibit decreased inhibition (i.e. are resistant) to a covalent and/or irreversible BTK inhibitor. Also described herein modifications of PLCy2 and CARD 11 polypeptides that confer resistance to treatment with a BTK inhibitor. Described herein are diagnostic methods for detecting the modified polypeptides and nucleic acids encoding the modified polypeptides and applications of the methods thereof. Described herein are compositions, combinations, and kits containing the modified polypeptides and methods of using the modified polypeptides. Also described herein are methods of using modified BTK polypeptides as screening agents for the identification and design of second-generation BTK inhibitors.
    Type: Grant
    Filed: July 23, 2013
    Date of Patent: March 23, 2021
    Assignees: Pharmacyclics LLC, Cornell University
    Inventors: Betty Chang, Joseph J. Buggy, Susanne M. Steggerda
  • High-efficiency transmission-mode diamond scintillator for quantitative characterization of X-ray beams
    Patent number: 10954607
    Abstract: The luminance of a transmission mode X-ray scintillator diamond plate is dominated by induced defect centers having an excited state lifetime less than 10 msec, and in embodiments less than 1 msec, 100 usec, 10 used, 1 used, 100 nsec, or even 50 nsec, thereby providing enhanced X-ray luminance response and an X-ray flux dynamic range that is linear with X-ray flux on a log-log scale over at least three orders of magnitude. The diamond plate can be a single crystal having a dislocation density of less than 104 per square centimeter, and having surfaces that are ion milled instead of mechanically polished. The defect centers can be SiV centers induced by silicon doping during CVD diamond formation, and/or NV0 centers formed by nitrogen doping followed by applying electron beam irradiation of the diamond plate and annealing.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: March 23, 2021
    Assignees: Euclid Techlabs, LLC, Center for Technology Licensing (“CTL”) at Cornell University, Research Foundation of The City University of New York
    Inventors: Sergey Antipov, Stanislav Stoupin, Alexandre M. Zaitsev
  • Use of adenosine receptor signaling to regulate P-gp function
    Patent number: 10953015
    Abstract: The present invention relates to a method of inhibiting p-glycoprotein (P-gp) expression in a cell. The method involves contacting a cell expressing P-gp with a composition comprising an effective amount of an A2A adenosine receptor (A2A AR) agonist to inhibit P-gp expression in the cell. Methods of enhancing the bioavailability of a chemotherapeutic in a subject having multi-drug resistant (MDR) cancer and methods of increasing P-gp-mediated efflux in a cell are also disclosed.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: March 23, 2021
    Assignee: Cornell University
    Inventor: Margaret Bynoe
  • Tissue scaffold materials for tissue regeneration and methods of making
    Patent number: 10953135
    Abstract: Disclosed herein are tissue scaffold materials with microspheres of one density embedded in hydrogel of a different density. The disclosed materials have improved ability to facilitate cellular invasion and vascularization for wound healing and tissue regeneration. The inventors have found that materials having components with different densities promotes invasion of cells, including desirable cells such as fibroblasts and endothelial precursor cells, into the scaffold.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: March 23, 2021
    Assignee: Cornell University
    Inventors: Jason Spector, Abraham D. Stroock, John Morgan
  • Proteasome inhibitors and uses thereof
    Patent number: 10954226
    Abstract: The compounds of the present invention are represented by the following compounds having Formula (I) where the substituents R, R1-R5, k, m, n, and q are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders, infectious disease, or for providing immunosuppression for transplanted organs or tissues.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: March 23, 2021
    Assignee: Cornell University
    Inventors: Gang Lin, Carl Nathan, Pradeep K. Singh, Lei Shi, Laura Kirkman
  • Polarization field assisted heterostructure design for efficient deep ultra-violet light emitting diodes
    Patent number: 10957817
    Abstract: A polarization field assisted DUV-LED including a bottom substrate and a n-contact/injection layer formed on the bottom substrate. The n-contact/injection layer includes: a first region for accommodating strain relaxation; a second region for lateral access with a low sheet resistance and higher conductivity compared to the first region to minimize resistive losses and heat generation; and a third region of a graded vertical injection layer with low vertical resistance to minimize heat loss due to vertical resistance. The DUV-LED also includes a p-contact region, and an emitting active region between the n-contact/injection layer and the p-contact region. The injection of electrons and holes into quantum wells proceeds due to tunneling of electrons and holes under the barriers due to less than 2 nm thickness of barriers. This carrier injection lowers the Turn ON voltage of LEDs and reduces heat generation.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: March 23, 2021
    Assignee: Cornell University
    Inventors: Sm Islam, Vladimir Protasenko, Huili Grace Xing, Debdeep Jena
  • Execution time prediction for energy-efficient computer systems
    Patent number: 10949260
    Abstract: Methods, systems, and devices of using prediction-guided resource allocation technologies for software applications are disclosed, comprising generating a plurality of program features that impact execution time of a plurality of program tasks; predicting execution time of the plurality of program tasks on one or more computing cores using the plurality of program features, wherein each of the plurality of program features is mapped to an execution time estimate on a selected computing core; and con trolling resources for the one or more computing cores based on a predicted execution time of the plurality of program tasks.
    Type: Grant
    Filed: December 4, 2016
    Date of Patent: March 16, 2021
    Assignee: Cornell University
    Inventors: Daniel Lo, Tao Chen, Gookwon Edward Suh, Taejoon Song
  • Hybrid materials and nanocomposite materials, methods of making same, and uses thereof
    Patent number: 10950849
    Abstract: Hybrid materials and nanocomposite materials, methods of making and using such materials. The nanoparticles of the nanocomposite are formed in situ during pyrolysis of a hybrid material comprising metal precursor compounds. The nanoparticles are uniformly distributed in the carbon matrix of the nanocomposite. The nanocomposite materials can be used in devices such as, for example, electrodes and on-chip inductors.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: March 16, 2021
    Assignee: Cornell University
    Inventors: Lynden A. Archer, Zichao Yang, Shyamal Kumar Das
  • Adenoassociated viral mediated persistant anti-VEGF therapy for ovarian cancer
    Patent number: 10946094
    Abstract: The invention provides a method of treating ovarian cancer in a patient by administering to the patient an adeno-associated virus (AAV) vector encoding an anti-VEGF antibody or antigen binding fragment thereof.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: March 16, 2021
    Assignee: Cornell University
    Inventors: Ronald G. Crystal, Arash Rafii Tabrizi
  • METHODS FOR QUANTIFYING LIGAND EFFICACY IN G-PROTEIN COUPLED RECEPTORS USING SINGLE-MOLECULE FLUORESCENCE ENERGY TRANSFER
    Publication number: 20210072155
    Abstract: Disclosed herein are methods for providing a molecular efficacy of a ligand, especially when utilizing single-molecule fluorescence resonance energy transfer (“smFRET”) imaging, as well as compounds useful in such methods.
    Type: Application
    Filed: August 31, 2018
    Publication date: March 11, 2021
    Applicant: Cornell University
    Inventors: Scott C. Blanchard, Gabriel Glenn Gregorio, Brian Kobilka
  • Stretchable electroluminescent devices
    Patent number: 10944072
    Abstract: A light emitting capacitor can include a first and second electrode, an electroluminescent layer, and at least one elastomeric layer. The electroluminescent layer, which can include an elastomeric material doped with semiconducting nanoparticles, can be disposed between the first and second electrodes. The elastomeric layer can encapsulate the first electrode, second electrode, and electroluminescent layer. The first and second electrodes can be hydrogel or conductive electrodes. The light emitting capacitor can provide dynamic coloration or sensory feedback. The light emitting capacitor can be used in, for example, robotics, wearables (displays, sensors, textiles), and fashion.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: March 9, 2021
    Assignee: Cornell University
    Inventors: Chris M. Larson, Robert F. Shepherd, Bryan N. Peele, Sanlin S. Robinson, Shuo Li